The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.
 
Sakti Chakrabarti
No Relationships to Disclose
 
Jaskanwal Deep S. Sara
No Relationships to Disclose
 
Ronstan Lobo
No Relationships to Disclose
 
Rachel Eiring
No Relationships to Disclose
 
Heidi D. Finnes
No Relationships to Disclose
 
Jessica L Mitchelll
Speakers' Bureau - Physicans' Education Resource; Research To Practice
 
Mindy L. Hartgers
No Relationships to Disclose
 
Akiko Okano
No Relationships to Disclose
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Ipsen (Inst); Lexicon (Inst); Merrimack (Inst)
Research Funding - Boston Biomedical (Inst); Esanex (Inst); Ipsen (Inst)
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; Merck Sharp & Dohme